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ABSTRACT
Introduction Pancreatic ductal adenocarcinoma (PDAC) 
has a dismal prognosis with an overall 5- year survival of 
approximately 8%. The success in reducing the mortality 
rate of PDAC is related to the discovery of new therapeutic 
agents, and to a significant extent to the development of 
early detection and prevention programmes. Patients with 
new- onset diabetes mellitus (DM) represent a high- risk 
group for PDAC as they have an eightfold higher risk of 
PDAC than the general population. The proposed screening 
programme may allow the detection of PDAC in the early, 
operable stage. Diagnosing more patients in the curable 
stage might decrease the morbidity and mortality rates of 
PDAC and additionally reduce the burden of the healthcare.
Methods and analysis This is a prospective, multicentre 
observational cohort study. Patients ≥60 years old diagnosed 
with new- onset (≤6 months) diabetes will be included. 
Exclusion criteria are (1) Continuous alcohol abuse; (2) 
Chronic pancreatitis; (3) Previous pancreas operation/
pancreatectomy; (4) Pregnancy; (5) Present malignant 
disease and (6) Type 1 DM. Follow- up visits are scheduled 
every 6 months for up to 36 months. Data collection is 
based on questionnaires. Clinical symptoms, body weight 
and fasting blood will be collected at each, carbohydrate 
antigen 19–9 and blood to biobank at every second visit. The 
blood samples will be processed to plasma and analysed 
with mass spectrometry (MS)- based metabolomics. The 
metabolomic data will be used for biomarker validation for 
early detection of PDAC in the high- risk group patients with 
new- onset diabetes. Patients with worrisome features will 
undergo MRI or endoscopic ultrasound investigation, and 
surgical referral depending on the radiological findings. One 
of the secondary end points is the incidence of PDAC in 
patients with newly diagnosed DM.
Ethics and dissemination The study has been approved 
by the Scientific and Research Ethics Committee of the 
Hungarian Medical Research Council (41085-6/2019). We 
plan to disseminate the results to several members of the 
healthcare system includining medical doctors, dietitians, 
nurses, patients and so on. We plan to publish the results 
in a peer- reviewed high- quality journal for professionals. In 
addition, we also plan to publish it for lay readers in order 
to maximalise the dissemination and benefits of this trial.
Trial registration number  ClinicalTrials. gov 
NCT04164602
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) 
is a rare disease with a lifetime prevalence 
of 1.39%, but its prevalence is continuously 
increasing.1–3 The prognosis is extremely 
poor: it has a 5- year survival rate of only 
7%–8%,4 and this rate has barely improved in 
the last 40 years.5 PDAC will be the second 
leading cause of cancer- related death by 
2030.6 The high mortality rate is a conse-
quence of delayed diagnosis: in the absence 
of specific symptoms, PDAC is often diag-
nosed at an advanced stage. Surgery is the 
Strengths and limitations of this study
 ► As patients are included prospectively, the study 
will yield a cohort to examine the metabolic chang-
es that coincide with the occurrence of pancreatic 
ductal adenocarcinoma (PDAC) at a very early stage 
before it is diagnosed.
 ► The criteria for the diagnoses of diabetes and PDAC 
will be uniformly applied throughout the study pe-
riod, moreover the diagnosis of pancreatic cancer 
will be confirmed with a high level of certainty in 
all subjects.
 ► Taking part in the screening is connected to a very 
low burden, as the blood collection is only minimally 
invasive.
 ► All patients will be monitored closely and frequently, 
which will increase the survival of all participants, 
especially the high- risk patients.
 ► It might be really difficult to include the required 
number of patients, considering that PDAC is a 
rare disease, and the elderly population has more 
comorbidities which makes our observations more 
difficult, and leads to a higher follow- up loss during 
the 36 months.
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only curative treatment at this moment. Unfortunately, 
only 20% of the patients are eligible for curative resec-
tion at the time of the diagnosis because of the presence 
of metastases and locoregional infiltration.7 The success 
in reducing the mortality rate of PDAC is related to a 
significant extent to the development of early detection 
and prevention programmes. An effective screening 
programme is needed for the early diagnosis of PDAC in 
the asymptomatic stage to improve the prognosis. Due to 
the low lifetime prevalence, population- based screening 
is neither feasible nor cost- effective. It is recommended 
that subjects at high risk of PDAC should be screened.8
PDAC and DM
Patients with diabetes mellitus (DM) have an eightfold 
higher risk of developing PDAC within 2–3 years after 
the diagnosis of diabetes relative to the general popula-
tion.9 In a meta- analysis which included 36 studies, indi-
viduals in whom DM had only recently been diagnosed 
(<4 years) had a 50% increased risk of PDAC as compared 
with individuals who had diabetes for >5 years.10 Another 
meta- analysis of 35 cohort studies showed that DM was 
associated with an increased risk of PDAC (summary rela-
tive risks (RRs)=1.94; 95% CI 1.66 to 2.27). Interestingly, 
the risk decreased with the duration of diabetes (5.38 for 
<1 year, 1.95 for 1–4 years, 1.49 for 5–9 years, 1.47 for ≥10 
years), thus providing evidence that diabetes in patients 
with PDAC is caused by the cancer itself.11 In these cases, 
patients are actually suffering from diabetes type 3 c 
(T3cDM). Diabetes is already prevalent in small PDACs,12 
and what is more important, is that diabetes occurs before 
the tumour is radiologically detectable.13 A population- 
based study found that approximately 1% of patients 
with new- onset diabetes at age 50 years or older will be 
diagnosed with PDAC within 3 years of first meeting the 
criteria for diabetes, and 56% of these within 6 months 
of meeting the criteria for diabetes.9 Recognition of new- 
onset diabetes as an early manifestation of PDAC could 
lead to diagnosis of asymptomatic, early stage PDAC.14 In 
our recent prospective study, the prevalence of PDAC in 
patients with new- onset diabetes was significantly higher 
than in the general population (the value of the stan-
dardised incidence ratio for PDAC in patients with new- 
onset type 2 diabetes was 198.6 (95% CI 6.25 to 46.9)); 
therefore, screening seems to be beneficial for detecting 
PDAC in this patient population.15 Weight loss in patients 
with pancreatic carcinoma- associated DM often precedes 
the onset of diabetes, while new- onset primary type 2 DM 
is typically associated with weight gain.16 The paradoxical 
development of diabetes in the face of ongoing weight 
loss may be an important clue to diagnose PDAC in 
patients with new onset of diabetes.
Screening modalities
The carbohydrate antigen 19–9 (CA19-9) is currently 
the only blood- based biomarker in clinical use for 
PDAC. The sensitivity of this marker for PDAC is 75%, 
the specificity is 90%, the positive predictive value 
(PPV) is 69% and the negative predictive value (NPV) 
is 90%.17 These values fall below the required character-
istics of a reliable screening test;10 18 therefore, serum 
CA19-9 measurement is not suitable for screening for 
PDAC. Imaging modalities represent the gold stan-
dard for diagnosing PDAC. The first choice is trans-
abdominal ultrasonography, however, its sensitivity in 
PDAC diagnosis is only 50%–70%. Its accuracy is low in 
tumours <1 cm, which are usually operable and nega-
tively influenced by obesity and meteorism.19 CT has a 
better accuracy in diagnosing PDAC; however, the low 
prevalence of PDAC and radiation exposure associ-
ated with the modality prevents it from being used as 
a screening test. The odds for a correct diagnosis are 
also high employing endoscopic ultrasound (EUS) or 
endoscopic retrograde cholangiopancreatography, 
but again the low prevalence of PDAC in combination 
with the burden of the endoscopic intervention to the 
patient preclude the application of these diagnostic 
methods for screening. Furthermore, it is not econom-
ically feasible to employ CT or endoscopic imaging for 
screening as these methods are associated with high 
costs to the healthcare system.
The success of the strategy of using new- onset diabetes 
as a screening tool to identify subjects with a high likeli-
hood of having asymptomatic PDAC will depend on our 
ability to differentiate PDAC- associated diabetes from the 
more common type 2 diabetes. PDAC- induced diabetes 
is thought to be a paraneoplastic phenomenon involving 
the release of products from the tumour rather than a 
result of the destruction of the pancreas due to malig-
nant infiltration.20 21 Data on incidence of PDAC in new- 
onset DM is rare; numbers of 0.25%,22 0.85%9 and 3.6%23 
have been reported. Therefore, to enable a diagnostic 
follow- up of new onset of diabetes, a further enrich-
ment of this group is needed,14 24 25 for example, elderly 
subjects (age is an independent risk factor for PDAC), 
weight loss26 or smoking.
A biomarker panel consisting of nine metabolites plus 
the established protein CA19-9 was recently identified 
by Mayerle et al with 89.9% sensitivity, 91.3% specificity 
and 99.8% NPV for differentiating PDAC from chronic 
pancreatitis.27 Employing the same methods, a biomarker 
panel for differential diagnosis between PDAC and non- 
cancer- related diabetes was identified. The metabolite 
signature needs validation in an independent test cohort, 
which will be enabled with the present study. Provided the 
biomarker is validated, the panel could be effective for 
screening of the high- risk group patients diagnosed with 
new- onset DM.
Aims of the project
1. Estimate the incidence of PDAC in patients with new- 
onset diabetes.
2. Diagnose PDAC in an early operable stage.
3. Validate a biomarker that distinguishes patients with 
PDAC- caused T3cDM from patients with type-2 diabe-
tes mellitus (T2DM).
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METHODS AND ANALYSIS
Design
This is a prospective, multicentre, observational cohort 
study aiming to validate a biomarker panel in the early 
stage of PDAC. The data collection is based on question-
naires, and blood samples will be drawn from all patients. 
The questionnaires (Form A at recruitment, Form B 
at every follow- up visit) will be filled by every included 
patient.
The inclusion criteria of this study are the following: 
(1) Patients over 60 years of age; (2) Diabetes diag-
nosed within 6 months (newly diagnosed)—diagnostical 
criteria are based on the Diabetes Control and Compli-
cations Trial (table 1).3 28 The participants signed written 
informed consent.
Exclusion criteria are as follows: (1) Continuous alcohol 
abuse; (2) Chronic pancreatitis; (3) Previous pancreas 
operation/pancreatectomy; (4) Pregnancy; (5) Present 
malignant disease; and (6) Type 1 DM. Patients with 
chronic pancreatitis were excluded because a metabolic 
signature differentiating between chronic pancreatitis 
and patients with PDAC has already been published27 
and is currently further evaluated by the META- PAC 
consortium, while the present study aims to differentiate 
between patients with PDAC- caused new- onset diabetes 
and new- onset diabetes due to other causes.
Sample size
Mayerle et al27 found that the biomarker signature in 
question could distinguish patients with PDAC from 
those without with an 89.9% sensitivity (marginal error 
8.9%) and 81.3% specificity (marginal error 10.3%). 
Chari et al9 concluded that elderly subjects with new- onset 
DM has eight times higher risk for pancreatic cancer than 
a person of similar age and sex without DM. In the light of 
the epidemiological data it is suggested that in Hungary 
the prevalence of PDAC is considerably higher than that 
compared with other countries’,5 we assumed a 2% prev-
alence for PDAC. In reference to these data, sample size 
calculation suggests that 2661 patients will need to be 
enrolled in order to confirm or reject the hypothesis for 
the primary end point with a 10% dropout, 80% power 
and 95% significance level. The recruitment period is 
planned to last 36 months, and all included patients will 
be followed for 36 months.
Duration
The first recruiting centre will be initialized on 1 July 
2019. Start of the patient recruitment: 31 January 2020. 
Planned completion of the study recruitment: 30 January 
2023.
Clinical data and clinical end points
Essential baseline clinical data
Age, sex, body weight, body mass index, date of DM diag-
nosis, date of sampling, comorbidities, antidiabetic medi-
cation, clinical symptoms, histology and stage of PDAC.
Primary clinical end points
The sensitivity, specificity, PPV, NPV and accuracy of the 
biomarker test.
Secondary end points
(1) Mortality rate of PDAC in patients with new- onset 
diabetes; (2) The proportion of localised and resectable 
PDAC; (3) Change in body weight before visit 1 and 
during visits 2–6; (4) Change in fasting blood glucose and 
haemoglobin A1c (HbA1c) before visit 1 and during visits 
2–6; (5) Antidiabetic medications and the risk of PDAC; 
(6) Presence of concomitant diseases; (7) Smoking and 
alcohol intake; (8) Incidence of PDAC in patients with 
new- onset diabetes; (9) Cost- benefit analysis.
Study protocol
Patients with diabetes will be recruited by our diabetolo-
gist and collaborating family physicians based on a recent 
(<6 months) laboratory test (table 1). Visit 0 is sched-
uled within 2 weeks from the referral (figure 1). Patients 
who meet study entry criteria and no exclusion, will be 
informed and offered to participate in the study, however 
signed informed consent will be necessary for inclu-
sion. Clinical data, body weight and worrisome features 
(unintentional weight loss: 5% of body weight within 6 
months without knowing the reason,29 abdominal pain/
discomfort, abnormal laboratory data, unstable glucose 
metabolism despite adequate diet and medical treatment 
and without intercurrent infection) will be recorded at 
visit 0, and a fasting blood sample will be taken for assess-
ment of laboratory data and metabolomics. C- peptide 
and glutamic acid decarboxylase antibodies will be deter-
mined to classify diabetes at visit 0. Patients with type 1 
Table 1 Diagnostic criteria of diabetes mellitus
Parameter Value and unit Description
Fasting plasma glucose ≥126 mg/dL
(7.0 mmol/L)
Fasting is defined as no caloric intake for at least 8 hours.
2- hour plasma glucose ≥200 mg/dL (11.1 mmol/L) Oral glucose tolerance test. The test should be performed as 
described by the WHO, using a glucose load containing the 
equivalent of 75 g anhydrous glucose dissolved in water.
HbA1c ≥6.5%
(48 mmol/mol)
The test should be performed in a laboratory using a method 
that is National Glycohemoglobin Standardization Program 
(NGSP) certified and standardised to the Diabetes Control and 
Complications Trial (DCCT) assay.
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DM will be excluded. If worrisome features are present at 
Visit 0, MRI or EUS is performed. Unambiguous PDAC 
lesions (>1 cm or seen also by MRI) will be referred to 
surgery for resection. In case of ambiguous lesions in the 
pancreas, EUS- fine needle aspiration will be performed. 
Visits 1–5 are scheduled every 6 months. Clinical symp-
toms, body weight, laboratory data (fasting blood glucose, 
HbA1c, liver and renal function, lipids, blood count) will 
be collected at each visit. Blood to biobank and CA19-9 
will be taken at every 12 months. The follow- up will be 
closed at 36 months.
Biochemical methods
After informed consent, fasted (overnight, at least 8 hours) 
patients’ blood samples will be drawn into an EDTA tube. 
Blood tubes (9 mL) are centrifuged within 2 hours after 
blood draw using a swing- out rotor at 2000 × g for 10 min. 
The sample processing is done at room temperature and 
the centrifuge is temperature- controlled at 19°C–21°C. 
After centrifugation, the supernatant is carefully removed, 
transferred to a fresh 9 mL tube and gently mixed in 
order to homogenise any gradient that might have been 
generated in the plasma supernatant. After that, the 
plasma is transferred in 0.5 mL aliquots to tubes (either 
Eppendorf Safe- Lock- Tubes 2 mL or Sarstedt Screw cap 
micro tubes 2 mL) and stored at −80°C, in a dedicated 
freezer (≤6 hours from centrifuge to freezer). Biomarkers 
will be determined comparing metabolite levels in plasma 
samples from patients diagnosed with PDAC and cancer- 
free patients with diabetes.26 CA19-9 determination is 
performed centralised at a certified clinical laboratory 
applying a cut- off of 37 U/mL as a classifier.
Cost of the biomarker test, quality- adjusted life years and 
incremental cost- effectiveness ratio will be determined.
Metabolite profiling (MxP)
MxP global profiling
Two types of mass spectrometry (MS) analyses are 
applied. GC–MS (gas chromatography- MS; Agilent 6890 
GC coupled to an Agilent 5973 MS System, Agilent, Wald-
bronn, Germany) and liquid chromatography- MS/MS 
(LC–MS/MS; Agilent 1100 high performance LC (HPLC)- 
System, Agilent, Waldbronn, Germany, coupled to an 
Applied Biosystems API4000 MS/MS- System, Applied 
Biosystems, Darmstadt, Germany) are used for a metabo-
lite profiling approach.30 Fractionation and derivatisation 
of samples and detection technologies have been previ-
ously described.31–34 Proteins are removed from plasma 
samples (60 µl) by precipitation. Subsequently, polar and 
non- polar fractions are separated for both GC–MS and 
LC–MS/MS analyses by adding water and a mixture of 
ethanol and dichloromethane. For GC–MS analyses, the 
non- polar fraction is treated with methanol under acidic 
conditions to yield the fatty acid methyl esters derived 
from free fatty acids and hydrolysed complex lipids. The 
polar and non- polar fractions are further derivatised 
with O- methyl- hydroxylamine hydrochloride (20 mg/mL 
in pyridine) to convert oxo- groups to O- methyloximes 
and subsequently with a silylating agent (N- Methyl- N- 
(trimethylsilyl) trifluoroacetamide) before GC–MS anal-
ysis. For LC–MS/MS analyses, both fractions are dried 
and subsequently reconstituted in appropriate solvent 
mixtures. HPLC is performed by gradient elution using 
methanol/water/formic acid on reversed phase separa-
tion columns.
MxP lipids
MxP lipids cover profiling of sphingolipids (ceramides, 
sphingomyelins and sphingobases). The metabolites are 
analysed in a semiquantitative approach (ie, relative to a 
pool). Total lipids are extracted from plasma by liquid/
liquid extraction using chloroform/methanol. The lipid 
extracts are subsequently fractionated by normal phase 
liquid LC into different lipid groups according to the 
references.31 35 The fractions are analysed by LC- MS/MS 
using electrospray ionisation and atmospheric pressure 
chemical ionisation with detection of specific multiple 
reaction monitoring transitions for sphingomyelins and 
ceramides, respectively.
Figure 1 Flow chart of the study protocol. *Weight loss 
(except at visit 0), abdominal pain/discomfort, abnormal 
laboratory data, unstable glucose metabolism despite the 
adequate diet and medical treatment and without intercurrent 
infection (except at visit 0). **Fasted (overnight, at least 8 
hours) patients’ blood samples at room temperature will be 
drawn into an EDTA tube. Within 2 hours after blood draw 
samples will be at 19°C–21°C. After centrifugation, the 
supernatant is carefully removed. After that, the plasma is 
transferred in 0.5 ml aliquots to tubes and stored at −80°C, 
in a dedicated freezer (≤6 hours from centrifuge to freezer). 
CA19-9, carbohydrate antigen 19–9; EUS, endoscopic 
ultrasound; GADA, glutamic acid decarboxylase antibodies.
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Data normalisation
Details of data normalisation have been published.27 
Metabolite profiling based on a semiquantitative analyt-
ical platform results in relative metabolite levels (‘ratio’) 
to a defined reference. To support this concept and to 
allow an alignment of different analytical batches, two 
different reference sample types are run in parallel 
throughout the whole process. First, a project pool is 
generated from aliquots of all samples and measured 
with four replicates within each analytical sequence that 
comprised 24 samples. For all semiquantitatively analysed 
metabolites, the results of each analyte from each sample 
are normalised against the median of the corresponding 
analyte in the pool reference samples within each analyt-
ical sequence to provide pool- normalised ratios. This 
process step compensates for interinstrumental and 
intrainstrumental variation, that is, variability that occurs 
when different analytical sequences are analysed by 
different devices. Second, to allow for an experiment- to- 
experiment alignment of semiquantitative data, MxPool 
(a large pool of a commercial human EDTA plasma suited 
for alignment of MxP studies) is analysed with 12 repli-
cated samples, and the pool- normalised ratios are further 
normalised to the median of the MxPool samples, that 
is, ratios from this study are on the same level and there-
fore comparable with data from other studies normalised 
to other aliquots of the same MxPool. A rigorous quality 
control is performed on peak, analyte and sample levels 
and has been described previously.36
Data collection and follow-up
Data collection is based on questionnaires, and will be 
stored in a personalised electronic database (electronic 
case report form - eCRF). Form A: contains all antro-
pometric parameters, routine clinical chemistry tests, 
fasting blood glucose and HbA1c. Follow- up visits will 
be scheduled by the patient registration system every 6 
months. Blood will be taken for biomarker identification 
with metabolomics and CA19-9 determination at every 12 
months. The total follow- up period is 3 years.
Pancreas adenocarcinoma will be diagnosed by histo-
logical examination.
Data set analysis and normalisation
Descriptive statistics—mean, median, SD, quartiles and 
relative frequency—relative risk (dichotomous variables), 
independent two- sample T test (continuous variable) 
in the case of normal distribution, furthermore Mann- 
Whitney U test in case of lack of normal distribution will 
be performed. Logistic regression will be applied for 
exploring predictive factors. Affiliated statistical analyses 
will be performed with an error probability of 0.05 (type- I 
error probability).
Prior to statistical analysis, log10 transformation of 
ratios is conducted so that the data distribution becomes 
approximately normal. SIMCA- P V.14.0 (Umetrics AB, 
Umea, Sweden), TIBCO Spotfire V.7.12.0 and R V.3.3.4 
are used for data analyses and visualisations. Initially, an 
exploratory multivariate analysis (principal component 
analysis) is applied to log10- transformed ratios scaled to 
unit variance.
A simple linear model (ANOVA, package nlme) 
addressing additional clinical information and poten-
tially confounding factors such as ‘disease’, ‘age’, ‘body 
mass index’, ‘gender’ and ‘sample storage time’ as fixed 
effects is fitted to the data. Significance level is set to 5%. 
The multiple test problem for the number of metabolites 
is addressed by calculating the false discovery rate using 
the Benjamini and Hochberg method.37
To classify patients depending on their metabolic 
profiles a penalised logistic regression is fitted via Elastic 
Net Algorithm using the R package glmnet.37 Equal penal-
ties are used for both the L1 and the L2 norms. After-
wards the cut- off established previously on the biomarker 
identification data set is applied on the test data without 
retraining, and the performance is measured in terms of 
area under the curve (AUC), sensitivity and specificity. 
Confidence levels for the AUC are calculated using the 
binormal model for the receiver operating characteristic 
curve. When the sensitivity is fixed at a particular value, 
PPV, NPV and the accuracy become monotone functions 
of the specificity; and CIs for these estimates are obtained 
by transformation of the CI for the specificity. CIs for 
sensitivity, specificity and accuracy are obtained for the 
cut- off prespecified in the training data by the method 
of Clopper and Pearson for the binomial distribution. 
For PPV and NPV the CIs will be obtained by the method 
of Gart and Nam38 for ratios of binomial parameters 
as implemented in the R package pairwise CI.39 When 
comparing the biomarker and CA19-9 on the test data, 
differences in sensitivity and specificity will be tested with 
McNemar’s test.
Centres
The study will start with the following centres: University 
of Szeged, University of Pécs, University of Semmelweis, 
however, other centres are welcome to participate as an 
open label study. Completion of the letter of intent form 
will be mandatory for registering the participation of 
each institution.
PATIENT AND PUBLIC INVOLVEMENT
No patients are involved.
ETHICS AND DISSEMINATION
Trial registration
The trial has been registered at the  ClinicalTrials. gov 
(NCT04164602).
Ethical approval
The study has been approved by the Scientific and 
Research Ethics Committee of the Hungarian Medical 
Research Council (41085-6/2019). Protocol version: V1.0 
08.01.2019.
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Publication policy
Centres providing more than 50 patients can provide 
authors to the authorship list.
Dissemination policy
We plan to disseminate the results to several members of 
the healthcare system including medical doctors, dieti-
tians, nurses, patients, and so on. We plan to publish 
the results in a peer- reviewed high- quality journal for 
professionals. In addition, we also plan to publish it for 
lay readers in order to maximalise the dissemination and 
benefits of this trial.
DISCUSSION
PDAC has a dismal prognosis, which is due to its late 
diagnosis. The success in reducing the mortality rate of 
PDAC is related to the development of early detection 
and prevention programmes. Age and DM are known as 
risk factors of PDAC.9–11 14 15
The expected positive end point of this study is to vali-
date a biomarker panel in elderly patients diagnosed with 
diabetes; whether it is suitable for early stage diagnosis of 
a mostly incurable, high- mortality cancer, when surgery is 
still possible and the cancer can be cured. PDAC- induced 
diabetes belongs to the group T3cDM and in parallel, 
T3cDM means the highest- risk group for PDAC. Unfortu-
nately, it is still underdiagnosed in the clinical practice—
maybe because its symptoms are very similar to T2DM’s and 
its diagnosis is based on complex, expensive tests that are 
not routinely available.40 To diagnose patients with T3cDM 
based on these criteria would lead to enormous difficulties 
and it would not be a cost- effective screening method, which 
is unfavourable. While there are several pancreatic diseases 
that can cause T3cDM, this study focuses on the differences 
between PDAC- T3cDM and T2DM only. In that manner, this 
biomarker panel could be a diagnostic tool for the T3cDM 
subgroup PDAC- T3cDM. The test requires only one blood 
sample collection, which means that it is simple, repeatable, 
tolerable, minimally invasive, nearly painless, widely achiev-
able and relatively cheap—it fulfils all the criteria set for a 
screening method. Identifying PDAC in an earlier (still 
resectable) stage through surveillance of high- risk patients 
would increase surgical resection rate, cure rates and survival 
by 30%–40%. It would save lives, maintain better well- being 
among the population and would have an enormous finan-
cial benefit: the increasing number of successful surgical 
interventions leads to lower necessity of chemotherapy 
and palliative interventions (such as stent implantations or 
gastroenteroanastomosis operations); moreover it lowers 
the burden of the healthcare cost.
Trial organisation, committees and boards
The coordinator of the NODES Study is LC with the 
support of the Hungarian Pancreatic Study Group (HPSG- 
coordinating society, https:// tm- centre. org/ en/ study- 
groups/ hungarian- pancreatic- study- group/). HPSG has 
been running high- quality international, multicentre 
clinical trials since 2014 and has published the relevant 
guidelines for pancreatic diseases to improve patient care 
in pancreatology.41–49
The trial will be supported by the following committees:
Steering Committee (SC): This committee will be led by 
PH (gastroenterologist and internal medicine specialist). 
DI and EI will be the members in Szeged (HU).
International Translational Advisory Board: This board 
will involve gastroenterologists. The International Transla-
tional Advisory Board will regularly monitor the progress of 
the trial and might give recommendations to the SC.
Data Monitoring Committee: The Data Monitoring 
Committee will handle all the data and ensure that the 
data in the eCRF is accurate, complete and legible. The 
Data Management Plan will describe the detailed data flow. 
The data manager will validate the data from completed 
eCRFs, according to a Data Cleaning Plan. Any missing, 
implausible or inconsistent recordings in the eCRFs will 
be referred back to the investigator using a data query 
form, and will be documented for each individual subject 
before clean file status is declared. All changes to eCRFs 
will be recorded.
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